Cargando…

Comparative effectiveness and safety of direct oral anticoagulants versus warfarin among patients with recurrent venous thromboembolism

The comparative effectiveness and safety of oral anticoagulant therapies to prevent a second recurrent venous thromboembolism (VTE) remains undetermined. We aimed to compare the benefits and harms of direct oral anticoagulant (DOAC) and warfarin therapies in preventing second recurrent VTE and major...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Hye‐Rim, Dietrich, Eric A., Huang, Pei‐Lin, Lo‐Ciganic, Wei‐Hsuan, DeRemer, Christina E., Park, Haesuk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264957/ https://www.ncbi.nlm.nih.gov/pubmed/36891985 http://dx.doi.org/10.1111/cts.13510

Ejemplares similares

Trajectories of adherence to extended treatment with warfarin and risks of recurrent venous thromboembolism and major bleeding
por: Kang, Hye-Rim, et al.
Publicado: (2023)

Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism
por: Park, Haesuk, et al.
Publicado: (2022)

Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism
por: Fang, Margaret C., et al.
Publicado: (2021)

Management of Warfarin Anticoagulated Patients Choosing Hyperbaric Oxygen Treatments
por: DeRemer, Christina E., et al.
Publicado: (2019)

Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017
por: Lutsey, Pamela L., et al.
Publicado: (2019)

Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism
por: Fang, Margaret C., et al.
Publicado: (2023)

Direct oral anticoagulants and venous thromboembolism
por: Franchini, Massimo, et al.
Publicado: (2016)

Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study
por: Jun, Min, et al.
Publicado: (2017)

Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis
por: Niyomsri, Siwaporn, et al.
Publicado: (2023)

Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism – The SWAN Study
por: Hendriks, Thomas, et al.
Publicado: (2020)

Venous thrombosis recurrence risk according to warfarin versus direct oral anticoagulants for the secondary prevention of venous thrombosis
por: Zakai, Neil A., et al.
Publicado: (2021)

Recurrent Venous Thromboembolism in a Patient with Klippel-Trenaunay Syndrome Despite Adequate Anticoagulation with Warfarin
por: Asnake, Zekarias T, et al.
Publicado: (2020)

Therapeutic options for the treatment of venous thromboembolism in case of warfarin intolerance: Effects of novel oral anticoagulants
por: Kodani, Eitaro
Publicado: (2013)

Direct Oral Anticoagulants and Travel-related Venous Thromboembolism
por: Chamnanchanunt, Supat, et al.
Publicado: (2018)

Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan
por: Nakamura, Mashio, et al.
Publicado: (2017)

Direct oral anticoagulants for unusual‐site venous thromboembolism
por: Riva, Nicoletta, et al.
Publicado: (2021)

Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism
por: Masini, Marta, et al.
Publicado: (2023)

Post-polypectomy bleeding and thromboembolism risks associated with warfarin vs direct oral anticoagulants
por: Yanagisawa, Naohiro, et al.
Publicado: (2018)

Direct Oral Anticoagulants or Standard Anticoagulant Therapy in Fragile Patients with Venous Thromboembolism
por: López-Núñez, Juan J., et al.
Publicado: (2019)

Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism
por: Yhim, Ho-Young, et al.
Publicado: (2014)

Direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer
por: Planquette, Benjamin, et al.
Publicado: (2019)

Variability in the Calculation of Time in Therapeutic Range for the Quality Control Measurement of Warfarin
por: Siddiqui, Safia, et al.
Publicado: (2018)

Factors Influencing Prescribers' Decision for Extending Venous Thromboembolism Prophylaxis in the Medical Patient Population following Hospitalization
por: Ebied, Alex M., et al.
Publicado: (2020)

Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients
por: Song, Andrew B, et al.
Publicado: (2019)

Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants
por: Ay, C, et al.
Publicado: (2019)

Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants
por: Weitz, Jeffrey I., et al.
Publicado: (2017)

The Use of Direct Oral Anticoagulants in the Management of Venous Thromboembolism in Patients With Obesity
por: Younis, Moustafa, et al.
Publicado: (2020)

The role of direct oral anticoagulants in venous thromboembolic disease in gynecologic cancer
por: Park, Jeong-Yeol
Publicado: (2019)

Arguments for Using Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism
por: Chiorescu, Roxana Mihaela, et al.
Publicado: (2021)

Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis
por: Tun, Han Naung, et al.
Publicado: (2022)

Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: A population-based cohort study
por: Khan, Adeel M., et al.
Publicado: (2022)

The Safety of Direct Oral Anticoagulants Versus Warfarin Among Older Individuals With Acute Venous Thromboembolism and CKD: A Population-Based Cohort Study
por: Harel, Ziv, et al.
Publicado: (2022)

Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis
por: Elshafei, Mohamed Nabil, et al.
Publicado: (2020)

Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms
por: Huenerbein, Karlo, et al.
Publicado: (2020)

Venous thromboembolism recurrence among one-and-done direct oral anticoagulant users: a retrospective longitudinal study
por: Alberts, Mark, et al.
Publicado: (2023)

Efficacy of Direct Oral Anticoagulant into the Care of Venous Thromboembolism Related to Kumamoto Earthquake
por: Matsukawa, Mai, et al.
Publicado: (2018)

Efficacy and Safety of Direct Oral Anticoagulants for Risk of Cancer-Associated Venous Thromboembolism
por: Zeng, Jie, et al.
Publicado: (2019)

Current Management of Cancer-associated Venous Thromboembolism: Focus on Direct Oral Anticoagulants
por: Kim, Sang-A, et al.
Publicado: (2019)

Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism
por: Prins, Martin H, et al.
Publicado: (2013)

Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence
por: García-Escobar, I., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3mur3am4rmvd4gt6fgitqmmr1e